John R Kirwan1, Susan J Bartlett, Dorcas E Beaton, Maarten Boers, Ailsa Bosworth, Peter M Brooks, Ernest Choy, Maarten de Wit, Francis Guillemin, Sarah Hewlett, Tore K Kvien, Robert B Landewé, Amye L Leong, Anne Lyddiatt, Lyn March, James May, Pamela Lesley Montie, Enkeleida Nikaï, Pam Richards, Marieke M J H Voshaar, Wilma Smeets, Vibeke Strand, Peter Tugwell, Laure Gossec. 1. From the University of Bristol, Academic Rheumatology Unit, and the University of the West of England, Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, UK; Department of Medicine, McGill University, Montreal, Quebec, Canada; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA; Department of Occupational Sciences and Occupational Therapy, Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Departments of Epidemiology and Biostatistics, and Rheumatology, and Department of Medical Humanities, VU University Medical Center, Amsterdam, The Netherlands; National Rheumatoid Arthritis Society, Maidenhead, Berkshire, UK; Faculty of Health Sciences, University of Queensland, Royal Brisbane and Women's Hospital, Herston, Brisbane, Australia; Section of Rheumatology, Cardiff University School of Medicine, Cardiff, UK; Université de Lorraine, Université Paris Descartes, Paris, France; Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Department of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam and Atrium Medical Center Heerlen, Amsterdam, The Netherlands; Healthy Motivation, Bone and Joint Decade, Santa Barbara, California, USA; Cochrane Musculoskeletal Group, Institute of Population Health, Ottawa, Ontario, Canada; Department of Rheumatology, Royal North Shore Hospital, St. Leonards, New South Wales, Australia; Consumer Advisory Board, Arthritis Research Centre of Canada, Richmond, British Columbia, Canada; UCB Pharma S.A., Brussels, Belgium; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Université Pierre et Marie Curie (UPMC) - Paris 6, GRC-UMPC 08 (EEMOIS); AP-HP Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France.
Abstract
OBJECTIVE: At a previous Outcome Measures in Rheumatology (OMERACT) meeting, participants reflected on the underlying methods of patient-reported outcome (PRO) instrument development. The participants requested proposals for more explicit instrument development protocols that would contribute to an enhanced version of the "Truth" statement in the OMERACT Filter, a widely used guide for outcome validation. In the present OMERACT session, we explored to what extent these new Filter 2.0 proposals were practicable, feasible, and already being applied. METHODS: Following overview presentations, discussion groups critically reviewed the extent to which case studies of current OMERACT Working Groups complied with or negated the proposed PRO development framework, whether these observations had a more general application, and what issues remained to be resolved. RESULTS: Several aspects of PRO development were recognized as particularly important, and the need to directly involve patients at every stage of an iterative PRO development program was endorsed. This included recognition that patients contribute as partners in the research and not merely as subjects. Correct communication of concepts with the words used in questionnaires was central to their performance as measuring instruments, and ensuring this understanding crossed cultural and linguistic boundaries was important in international studies or comparisons. CONCLUSION: Participants recognized, endorsed, and were generally already putting into practice the principles of PRO development presented in the plenary session. Further work is needed on some existing instruments and on establishing widespread good practice for working in close collaboration with patients.
OBJECTIVE: At a previous Outcome Measures in Rheumatology (OMERACT) meeting, participants reflected on the underlying methods of patient-reported outcome (PRO) instrument development. The participants requested proposals for more explicit instrument development protocols that would contribute to an enhanced version of the "Truth" statement in the OMERACT Filter, a widely used guide for outcome validation. In the present OMERACT session, we explored to what extent these new Filter 2.0 proposals were practicable, feasible, and already being applied. METHODS: Following overview presentations, discussion groups critically reviewed the extent to which case studies of current OMERACT Working Groups complied with or negated the proposed PRO development framework, whether these observations had a more general application, and what issues remained to be resolved. RESULTS: Several aspects of PRO development were recognized as particularly important, and the need to directly involve patients at every stage of an iterative PRO development program was endorsed. This included recognition that patients contribute as partners in the research and not merely as subjects. Correct communication of concepts with the words used in questionnaires was central to their performance as measuring instruments, and ensuring this understanding crossed cultural and linguistic boundaries was important in international studies or comparisons. CONCLUSION:Participants recognized, endorsed, and were generally already putting into practice the principles of PRO development presented in the plenary session. Further work is needed on some existing instruments and on establishing widespread good practice for working in close collaboration with patients.
Entities:
Keywords:
OUTCOME AND PROCESS ASSESSMENT; PATIENT-REPORTED OUTCOMES; RANDOMIZED CONTROLLED TRIALS
Authors: Allison Tong; John Gill; Klemens Budde; Lorna Marson; Peter P Reese; David Rosenbloom; Lionel Rostaing; Germaine Wong; Michelle A Josephson; Timothy L Pruett; Anthony N Warrens; Jonathan C Craig; Benedicte Sautenet; Nicole Evangelidis; Angelique F Ralph; Camilla S Hanson; Jenny I Shen; Kirsten Howard; Klemens Meyer; Ronald D Perrone; Daniel E Weiner; Samuel Fung; Maggie K M Ma; Caren Rose; Jessica Ryan; Ling-Xin Chen; Martin Howell; Nicholas Larkins; Siah Kim; Sobhana Thangaraju; Angela Ju; Jeremy R Chapman Journal: Transplantation Date: 2017-08 Impact factor: 4.939
Authors: Maria-Antonietta D'Agostino; Maarten Boers; John Kirwan; Désirée van der Heijde; Mikkel Østergaard; Georg Schett; Robert B Landewé; Walter P Maksymowych; Esperanza Naredo; Maxime Dougados; Annamaria Iagnocco; Clifton O Bingham; Peter M Brooks; Dorcas E Beaton; Frederique Gandjbakhch; Laure Gossec; Francis Guillemin; Sarah E Hewlett; Margreet Kloppenburg; Lyn March; Philip J Mease; Ingrid Moller; Lee S Simon; Jasvinder A Singh; Vibeke Strand; Richard J Wakefield; George A Wells; Peter Tugwell; Philip G Conaghan Journal: J Rheumatol Date: 2014-03-01 Impact factor: 4.666
Authors: John D Pauling; Robyn T Domsic; Lesley A Saketkoo; Celia Almeida; Jane Withey; Hilary Jay; Tracy M Frech; Francesca Ingegnoli; Emma Dures; Joanna Robson; Neil J McHugh; Ariane L Herrick; Marco Matucci-Cerinic; Dinesh Khanna; Sarah Hewlett Journal: Arthritis Care Res (Hoboken) Date: 2018-08-16 Impact factor: 4.794
Authors: Laure Gossec; John Richard Kirwan; Maarten de Wit; Andra Balanescu; Cecile Gaujoux-Viala; Francis Guillemin; Anne-Christine Rat; Alain Saraux; Bruno Fautrel; Tore K Kvien; Maxime Dougados Journal: Clin Rheumatol Date: 2018-02-21 Impact factor: 2.980
Authors: Jin Kyun Park; Christopher A Mecoli; Helene Alexanderson; Malin Regardt; Lisa Christopher-Stine; María Casal-Domínguez; Ingrid de Groot; Catherine Sarver; Ingrid E Lundberg; Clifton O Bingham; Yeong Wook Song Journal: J Rheumatol Date: 2017-08-01 Impact factor: 4.666
Authors: Susan J Bartlett; Vivian P Bykerk; Roxanne Cooksey; Ernest H Choy; Rieke Alten; Robin Christensen; Daniel E Furst; Francis Guillemin; Serena Halls; Sarah Hewlett; Amye L Leong; Anne Lyddiatt; Lyn March; Pamela Montie; Ana Maria Orbai; Christoph Pohl; Marieke Scholte Voshaar; Thasia G Woodworth; Clifton O Bingham Journal: J Rheumatol Date: 2015-02-15 Impact factor: 4.666
Authors: Valérie Devauchelle-Pensec; Jacques-Eric Gottenberg; Sandrine Jousse-Joulin; Jean-Marie Berthelot; Aleth Perdriger; Eric Hachulla; Pierre Yves Hatron; Xavier Puechal; Véronique Le Guern; Jean Sibilia; Laurent Chiche; Vincent Goeb; Olivier Vittecoq; Claire Larroche; Anne Laure Fauchais; Gilles Hayem; Jacques Morel; Charles Zarnitsky; Jean Jacques Dubost; Philippe Dieudé; Jacques Olivier Pers; Divi Cornec; Raphaele Seror; Xavier Mariette; Emmanuel Nowak; Alain Saraux Journal: PLoS One Date: 2015-09-14 Impact factor: 3.240